These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3481660)

  • 1. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats.
    Hobbelen PM; Vogel GM; Meuleman DG
    Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orgaran (Org 10172): its pharmacological profile in experimental models.
    Meuleman DG
    Haemostasis; 1992; 22(2):58-65. PubMed ID: 1379965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients.
    ten Cate H; Henny CP; ten Cate JW; Büller HR; Mooy MC; Surachno S; Wilmink JM
    Thromb Res; 1985 Jul; 39(2):211-22. PubMed ID: 3161213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo activity of a new heparinoid.
    Ockelford PA; Carter CJ; Hirsh J
    Pathology; 1985 Jan; 17(1):78-81. PubMed ID: 4000717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs.
    Henny CP; Ten Cate H; Ten Cate JW; Moulijn AC; Sie TH; Warren P; Büller HR
    J Lab Clin Med; 1985 Aug; 106(2):187-96. PubMed ID: 4020247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.
    Bradbrook ID; Magnani HN; Moelker HC; Morrison PJ; Robinson J; Rogers HJ; Spector RG; Van Dinther T; Wijnand H
    Br J Clin Pharmacol; 1987 Jun; 23(6):667-75. PubMed ID: 3606928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans.
    Visser A; Meuleman DG
    Thromb Res; 1990 Jun; 58(5):469-79. PubMed ID: 2164263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
    Buchanan MR; Boneu B; Ofosu F; Hirsh J
    Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synopsis of the anticoagulant and antithrombotic profile of the low molecular weight heparinoid Org 10172 in experimental models.
    Meuleman DG
    Semin Thromb Hemost; 1989 Oct; 15(4):370-2. PubMed ID: 2479103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of intimal hyperplasia after arterial injury by heparins and heparinoid.
    Dryjski M; Mikat E; Bjornsson TD
    J Vasc Surg; 1988 Nov; 8(5):623-33. PubMed ID: 2460647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment.
    Ireland H; Lane DA; Flynn A; Anastassiades E; Curtis JR
    Thromb Haemost; 1986 Apr; 55(2):271-5. PubMed ID: 3715791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).
    Mikhailidis DP; Fonseca VA; Barradas MA; Jeremy JY; Dandona P
    Br J Clin Pharmacol; 1987 Oct; 24(4):415-24. PubMed ID: 3689624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
    De Boer A; Stiekema JC; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1991 Jul; 32(1):23-9. PubMed ID: 1716140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
    Vogel GM; van Amsterdam RG; Kop WJ; Meuleman DG
    Thromb Haemost; 1993 Jan; 69(1):29-34. PubMed ID: 8446935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Moolenaar AJ; Breimer DD
    Eur J Clin Pharmacol; 1991; 41(3):245-50. PubMed ID: 1748141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.
    de Boer A; Stiekema JC; Danhof M; van Dinther TG; Boeijinga JK; Cohen AF; Breimer DD
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2110-5. PubMed ID: 1759835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M; de Boer A; Magnani HN; Stiekema JC
    Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.